



Meeting on Editing Chapters of


ICH-ISHBT Guidelines on Synoptic Reporting of PBS, BMA & BMB

Friday, 14th August, 2026

ISHBT Head Office, Kolkata

The Indian Society of Haematology and Blood Transfusion (ISHBT) and the Indian College of Haematology (ICH) convened a meeting on Friday, 14th August 2026, at the ISHBT Head Office, Kolkata, for the editing and review of chapters of the ICH-ISHBT Guidelines on Synoptic Reporting of Peripheral Blood Smear (PBS), Bone Marrow Aspiration (BMA) and Bone Marrow Biopsy (BMB). The meeting brought together experts in haematology and laboratory medicine to discuss, review and

refine the chapters of the forthcoming guidelines. The participants focused on ensuring clarity, uniformity and practical applicability of synoptic reporting standards for PBS, BMA and BMB. The collaborative initiative by ICH and ISHBT aims to develop a comprehensive and standardized framework for reporting haematological investigations, supporting consistency in diagnostic practice and improving communication among clinicians and laboratory professionals. The meeting marked another important step towards the completion of the ICH-ISHBT Guidelines on Synoptic Reporting of PBS, BMA & BMB.



The book is relevant for postgraduate medical students in Internal medicine, pediatrics, pathology, D.M. / DNB students of clinical and laboratory haematology, sub-specialty haematology practitioners, and postgraduate medical college teachers.

Book Link:

https://lnkd.in/d_794FDq



ISHBT-ICH Haemophilia Compendium & Guideline Meeting

Saturday, 12th September, 2026

ISHBT Head Office, Kolkata

The Indian Society of Haematology and Blood Transfusion (ISHBT), in collaboration with the Institute of Child Health (ICH), organized the ISHBT-ICH Haemophilia Compendium & Guideline Meeting on 12th September 2026 at the ISHBT Head Office, Kolkata.

The meeting brought together eminent haematologists, clinicians, and experts in the field of haemophilia to discuss and contribute to the development of a comprehensive Haemophilia Compendium and Guideline. The academic deliberations focused on important aspects of haemophilia care, including diagnosis, treatment approaches, comprehensive patient management, complications, and current standards of care.

Experts participated in detailed discussions and reviewed various chapters to ensure that the proposed compendium and guidelines reflect contemporary clinical practices and address the needs of healthcare professionals involved in the management of haemophilia.

The meeting served as an important platform for academic exchange and collaborative contribution towards strengthening haemophilia care and education in India. ISHBT and ICH expressed their commitment to continuing this collaborative initiative and developing a practical, evidence-based resource for clinicians and healthcare professionals.

The successful meeting marked another significant step towards the preparation of the ISHBT-ICH Haemophilia Compendium & Guideline, with continued contributions from experts across the country.

15th National Haematology Quiz 2026 - State Round for Post Graduate Students

Thursday, 17th September, 2026

ISHBT Head Office, Kolkata

The 15th National Haematology Quiz 2026 for Post-Graduate Students – State Round was successfully held on 17th September 2026 at the Head Office of the Indian Society of Haematology and Blood Transfusion (ISHBT), Kolkata.

The quiz provided an engaging academic platform for postgraduate students to demonstrate and enhance their knowledge of haematology through a competitive and intellectually stimulating format. Participants enthusiastically took part in the quiz, reflecting their keen interest and commitment to the field of haematology.

The event was conducted under the aegis of ISHBT, with the objective of encouraging academic excellence, healthy competition, and greater interest in haematology among postgraduate students. ISHBT congratulates all the participating students and extends its best wishes to the successful participants for the forthcoming rounds of the National Haematology Quiz 2026.

ISHBT congratulates all the participating teams and wishes the qualifying teams the very best for the upcoming Zonal Round.

Zonal Round is scheduled to be held on 27th September 2026 at Mayfair, Bhubaneswar, Odisha.



67th Annual Conference of
Indian Society of Hematology & Blood Transfusion
HAEMATOCON 2026
Theme: - Advancing Hematology: From Evidence to Clinical Excellence
12th - 15th NOV, 2026 | Ahmedabad, India

Register Now - www.haematocon2026.in



Upcoming CMEs of ISHBT
CME on
Quality Assurance in Haematology Lab 2026
Organised by:
Indian Society of Haematology and Blood Transfusion
Date: 3rd October, 2026
Venue: Vivanta, Kolkata
Organising Secretary:
Prof. (Dr.) Tuphan Kanti Dolai
Register Now: <https://forms.gle/nTSxdHp8Teq5Xw7m6>





Masterclass of ISHBT
50th Masterclass of ISHBT
Topic: Hemoglobin HPLC Interpretation:
Finer nuances and Pitfalls
Speaker: Dr. Vijay Kumar
Date: Wednesday, 16th September, 2026,
Time: 07:00 P.M. IST
<https://forms.gle/Q3jeTte39pQcdwQM8>

Indian Journal of Haematology & Blood Transfusion (IJHBT)
Publishing model - Hybrid
Volume: 42, Issue: 5, Sep, 26
90 articles in this issue



Click below link to read or download
<https://link.springer.com/journal/12288/volumes-and-issues/42-4>



Newsletter
The Hematology India
VOLUME 3 - ISSUE 2
August 15, 2026
Click below link to read or download
<https://ishbtish.com/?p=web/newslettervolume>

Guideline By Indian College of Hematology (ICH)


Available On
Jaypee Brothers Medical Publishers,
Amazon & AIBH
<https://ishbtish.com/ich/guidelines.html>

What's new in Haematology in June, 2026 in Myeloma & Lymphoma

Myeloma
Study: Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Dimopoulos M, Schjesvold F, Fu C et al. The Lancet, 2026 Jun 14: S0140-6736(26)01088-3. doi: 10.1016/S0140-6736(26)01088-3
Interpretation
Mezigdomide–carfilzomib–dexamethasone provided a significant PFS benefit compared with carfilzomib–dexamethasone alone, with higher rates of grade 3 or 4 adverse events, including infections, which were mostly manageable with standard clinical practice and supportive care. These findings support mezigdomide–carfilzomib–dexamethasone as a clinically meaningful treatment option as early as first relapse in predominantly triple-class-exposed, anti-CD38 antibody-refractory and lenalidomide-refractory patients, a growing population with substantial unmet need.

THE LANCET
Study II: Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med. 2026 Jun 13. doi: 10.1056/NEJMoa2604657. Epub ahead of print. PMID: 42294841. Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV et al.
Conclusions: Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, both Tal-DP (talquetamab plus daratumumab and pomalidomide) and Tal-D (talquetamab plus daratumumab) led to significantly longer progression-free survival than DPd (daratumumab plus pomalidomide and dexamethasone).

Lymphoma
Study I: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. Toby A Eyre, Yuqin Song, Olivier Hermine Et al. J Clin Oncol 2026 Jul 1: JCO2600550. doi: 10.1200/JCO-26-00550.
Conclusion: Sonrotoclax demonstrated rapid, durable responses and manageable safety in heavily pretreated patients with R/R MCL, including high-risk subgroups, supporting its further clinical evaluation as an oral therapy for R/R MCL.

Journal of Clinical Oncology
Study II: Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis. Nicolas Gower, Pierre Feugier , Jason Westin et al. Blood 2026 Jun 18;147(25):3061-3068. doi: 10.1182/blood.2026033126.

In conclusion, the final analysis of RELEVANCE confirmed the absence of differences in efficacy outcomes between R2 and R-Chemo and the lack of new safety concerns, positioning R2 as a valid chemo-free alternative for patients with previously untreated, advanced FL. We believe these 10-year follow-up results constitute a benchmark for long-term expectations and comparisons with new promising chemo-free combinations currently tested in the front-line setting of FL.